Last reviewed · How we verify
PRS Regimen V
PRS Regimen V is a combination chemotherapy regimen designed to treat pulmonary tuberculosis through multi-drug antimycobacterial activity.
PRS Regimen V is a combination chemotherapy regimen designed to treat pulmonary tuberculosis through multi-drug antimycobacterial activity. Used for Pulmonary tuberculosis.
At a glance
| Generic name | PRS Regimen V |
|---|---|
| Sponsor | Shanghai Pulmonary Hospital, Shanghai, China |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
PRS Regimen V likely combines multiple first-line or second-line anti-tuberculosis agents to target Mycobacterium tuberculosis through different mechanisms, reducing bacterial load and preventing drug resistance. The specific composition and mechanism depend on the exact drugs included in the regimen, which is not publicly detailed in standard pharmaceutical databases.
Approved indications
- Pulmonary tuberculosis
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PRS Regimen V CI brief — competitive landscape report
- PRS Regimen V updates RSS · CI watch RSS
- Shanghai Pulmonary Hospital, Shanghai, China portfolio CI